---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-25-000009"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:10:14.274045+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Q4 net income $1.1M; FDA lifts hold on ENTR-601-44; cash $420M into Q2 2027

## Summary
- Q4 net income $1.1M vs loss $9.5M YoY; FY net income $65.6M vs loss $6.7M.
- Collaboration revenue $37.4M Q4, $210.8M FY; R&D expenses $33.4M Q4.
- Cash $420M as of Dec 31, 2024; runway expected into Q2 2027.
- FDA lifted clinical hold on ENTR-601-44; authorized US Phase 1b MAD study for exon 44 DMD.
- MHRA authorized UK Phase 1/2 study for ENTR-601-44; regulatory filings for ENTR-601-45 in UK/EU.

## SEC filing metadata
- accession: 0001689375-25-000009
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000009/0001689375-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000009/trda-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-25-000009
- JSON: https://secwatch.observer/filing/0001689375-25-000009.json
- Plain text: https://secwatch.observer/filing/0001689375-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.